Production of interleukin-2 by EL4 tumor cells induces natural killer cell-and T-cell-mediated immunity
MJW Visseren, M Koot, EIH van der Voort… - Journal of …, 1994 - journals.lww.com
Systemic administration of recombinant interleukin (rIL)-2 to cancer patients has met with
limited clinical success since, despite significant antitumor effects, its use is associated with
severe toxicity. Local production of IL-2 by IL-2 gene transfected tumor cells in murine model
systems has been reported to induce specific immunity—devoid of toxicity—to the parental
non-IL-2-producing tumor cells. We now report enhanced resistance in nonimmunized mice
to murine EL4 thymoma cells, producing murine IL-2 following gene transfer (EL4pIL-2). This …
limited clinical success since, despite significant antitumor effects, its use is associated with
severe toxicity. Local production of IL-2 by IL-2 gene transfected tumor cells in murine model
systems has been reported to induce specific immunity—devoid of toxicity—to the parental
non-IL-2-producing tumor cells. We now report enhanced resistance in nonimmunized mice
to murine EL4 thymoma cells, producing murine IL-2 following gene transfer (EL4pIL-2). This …